Fig 1: Fluorescent images of Panc-1 cells treated with different MoS2/siRNA nanocomplex formulations four hours after treatment. (A) PBS as blank control, (B) MoS2/PEG/PAH/FA (FA/MoS2) and (C) free KRAS-siRNAFAM (siKRASFAM) and (D) free HDAC1-siRNACyc3 (siHDAC1Cyc3) as negative control, the single delivery of KRAS-siRNAFAM (E) or HDAC1-siRNACyc3 (F) by MoS2/PEG/PAH/FA (FA/MoS2), and the co-delivery of KRAS-siRNAFAM and HDAC1-siRNACyc3 by (G) MoS2/PEG/PAH/FA (MoS2/FA) or (H) MoS2/PEG/PAH (MoS2). The cell nucleus is stained with DAPI (pseudo-colored in blue) and signals from FAM and Cyc3 are assigned in green and red, respectively.
Fig 2: Antitumor activities of MoS2-based nanoparticle formulations in a Panc-1 xenograft animal model. (A) Representative images of mouse and tumor tissues treated with (1) PBS, (2) FA/MoS2, (3) FA/MoS2 with NIR light, (4) FA/MoS2/scramble siRNA, (5) FA/MoS2/si(KRAS+HDAC1) or (6) FA/MoS2/si(KRAS+HDAC1) with NIR light. Mice treated by FA/MoS2/si(KRAS+HDAC1) with NIR light in the last group exhibited the smallest tumors. (B) Relative changes in tumor volume versus time of mice treated by PBS, FA/MoS2, FA/MoS2 with NIR light, FA/MoS2/scramble siRNA, FA/MoS2/si(KRAS+HDAC1) or FA/MoS2/si(KRAS+HDAC1) with NIR light, respectively. Relative tumor volume is defined as (V-V0)/V0, where V and V0 indicate the tumor volume on a particular day and day 0, respectively. Error bars represent SEMs for triplicate data. Mean tumor volumes are analysed using one-way ANOVA. Values are means ± SEM, n=3-5 tumors.
Fig 3: Tumors treated with KRAS siRNA NP demonstrate knockdown of the KRAS signaling pathway.(A) KPC-1 tumors from mice treated with KRAS-siRNA NP exhibit diminished KRAS protein level by Western blot analysis compared to scramble siRNA NP treated animals. (B) Looking at KPC-1 tumors from 7 mice/ group, with 5 20x images/ HPF taken, there was significant knockdown of pERK demonstrated in KRAS-siRNA NP (KRAS NP) treated mice. (C) H&E (top), and pERK IHC (bottom) images from control, scramble siRNA NP (SC NP) and KRAS NP treated mice. *=p < 0.05, standard error of the mean (SEM) shown.
Fig 4: NSCLC xenograft growth is decreased upon knockdown of KRAS via the anti-EGFR-mAB-protamine (P)/siRNA/P nanostructures.A Treatment scheme of the in vivo experiments. B–F Results of systemic in vivo application of targeted nanocarriers on A549 and SK-LU1 xenograft tumours. B Tumour growth curves for A549 (means–SEM). C Tumour growth curves for SK-LU1 (means–SEM). Both tumour growth curves show significant reduction of tumour growth in anti-KRAS siRNA treatment groups. D, E Size of excised tumours at the end of the respective experiments (X = individual tumours in anti-KRAS siRNA group were treated to extinction). F, G Weight statistics of the excised tumours (g, gram). H Proof of KRAS oncogene knockdown in excised tumour tissue by KRAS western blot ex vivo. Cntr control scrambled siRNA. *denote significant differences between groups (p < 0.05, two-sided t-test).
Fig 5: Levels of SIRT1 in the KRAS activation mouse model. (a) Representative photomicrograph of immunohistochemical staining of SIRT1 in the control and KRAS activation mouse. (b) The mRNA expression level of P4 target genes in the uterus from control and KRAS activation mice (n = 9). The results represent the mean ± SEM. *p < 0.05 and ***p < 0.001.
Supplier Page from Abcam for Anti-Ras antibody [4F3]